New Products Strategy: HIF-1 links hypoxia and inflammation

Pieter Droppert on Biotech Strategy Blog discusses the link between hypoxia and inflammation and how this cross-talk is implicated in cancer, infections and inflammatory bowel disease.

Understanding the link between hypoxia and inflammation may lead to potential targets for new product development.

One potential strategy is to target the hypoxia-inducible transcription factor (HIF).  EZN-2968, a novel HIF-1α antagonist is in phase I clinical trials.

, , , ,

error: Content is protected !!